Gilead Sciences, Inc. $GILD Shares Purchased by Noesis Capital Mangement Corp

Noesis Capital Mangement Corp grew its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 4.9% during the 3rd quarter, Holdings Channel reports. The firm owned 132,470 shares of the biopharmaceutical company’s stock after purchasing an additional 6,238 shares during the period. Gilead Sciences comprises 2.3% of Noesis Capital Mangement Corp’s investment portfolio, making the stock its 18th largest position. Noesis Capital Mangement Corp’s holdings in Gilead Sciences were worth $19,745,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of GILD. PFS Partners LLC raised its position in Gilead Sciences by 101.1% in the third quarter. PFS Partners LLC now owns 191 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 96 shares in the last quarter. Persistent Asset Partners Ltd acquired a new stake in Gilead Sciences in the 2nd quarter valued at about $25,000. Kimelman & Baird LLC bought a new position in shares of Gilead Sciences during the 2nd quarter valued at about $25,000. Toth Financial Advisory Corp boosted its position in shares of Gilead Sciences by 85.5% during the 3rd quarter. Toth Financial Advisory Corp now owns 217 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 100 shares in the last quarter. Finally, Trellis Wealth Advisors LLC acquired a new position in shares of Gilead Sciences in the 3rd quarter worth approximately $33,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Key Headlines Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: An analyst raised the fiscal 2026 EPS forecast for Gilead, signaling improved expectations for the company’s earnings outlook. FY2026 EPS Forecast for Gilead Sciences Raised by Analyst
• Positive Sentiment: Gilead’s latest deal highlights pharmaceutical-industry interest in oral peptide medicines. The transaction may support investor optimism about Gilead’s business-development strategy and longer-term growth opportunities in this emerging market. Gilead’s Latest Deal Shows Big Pharma’s Appetite for Oral Peptides
• Neutral Sentiment: Investors are preparing for Gilead’s third-quarter 2026 earnings report. Analysts are focused not only on revenue and EPS but also on operating metrics that could provide clues about product performance and the company’s outlook. Ahead of Gilead Q3 Earnings
• Neutral Sentiment: Recent coverage compares Gilead with Amgen as a dividend investment. Gilead offers a forward dividend yield above 2% and a lower payout ratio, although Amgen is reported to have stronger sales growth. Amgen vs. Gilead Sciences
• Negative Sentiment: The reported October short-interest data lists short interest at zero shares and a zero-day short-interest ratio despite describing a large increase. This apparent inconsistency limits its usefulness as a reliable signal of bearish positioning.

Analyst Ratings Changes

A number of analysts recently commented on GILD shares. Leerink Partners downgraded shares of Gilead Sciences from an “outperform” rating to a “market perform” rating and dropped their target price for the stock from $146.00 to $127.00 in a report on Tuesday, July 21st. Royal Bank Of Canada raised their target price on shares of Gilead Sciences from $123.00 to $126.00 and gave the stock a “sector perform” rating in a report on Thursday, October 8th. Jefferies Financial Group restated a “buy” rating and issued a $185.00 price target on shares of Gilead Sciences in a research report on Friday. Barclays dropped their price target on Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating on the stock in a report on Wednesday, July 29th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $155.00 price target on shares of Gilead Sciences in a report on Thursday, October 8th. Twenty-three research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $159.81.

Gilead Sciences Stock Up 1.7%

Gilead Sciences stock opened at $158.69 on Tuesday. Gilead Sciences, Inc. has a fifty-two week low of $114.02 and a fifty-two week high of $160.51. The firm’s 50 day simple moving average is $148.84 and its 200-day simple moving average is $138.77. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 1.09.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) EPS for the quarter, beating the consensus estimate of ($7.25) by $0.50. The business had revenue of $7.80 billion during the quarter, compared to the consensus estimate of $7.40 billion. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The firm’s quarterly revenue was up 10.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.01 EPS. Analysts anticipate that Gilead Sciences, Inc. will post -0.48 earnings per share for the current fiscal year.

Insider Activity

In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of the business’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $137.64, for a total transaction of $3,853,920.00. Following the sale, the insider directly owned 118,234 shares of the company’s stock, valued at $16,273,727.76. The trade was a 19.15% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew Dickinson sold 3,000 shares of the business’s stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $156.22, for a total transaction of $468,660.00. Following the sale, the chief financial officer directly owned 161,096 shares in the company, valued at approximately $25,166,417.12. This trade represents a 1.83% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 111,000 shares of company stock worth $15,877,860. 0.30% of the stock is owned by corporate insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.

Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.